Google
Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
+myBinderRelated Content
-
Today’s Faces of Sickle Cell Disease: Swee Lay Thein, MB, BS, FRCP, FRCPath, DScSwee Lay Thein was educated in both Mala...
-
American Sickle Cell Anemia AssociationThe American Sickle Cell Anemia Associat...
-
Aisha Walker, PhDDr. Walker is a Research Assistant Profe...
-
Barbara Speller Brown, DNP, MSNBarbara Speller-Brown, DNP, MSN, PNP-BC,...
-
University of Pittsburgh Medical Center, Heart and Vascular InstituteThe Vascular Medicine Institute at the U...
-
Four Solutions for Sickle Cell Disease SupportWhen Precious Lee was a year old, she be...
-
Pfizer rare disease introduces Council for Change to further help SCD patientsFollowing a report earlier thi...
